Julia E. Marquez-Arrico

@web.ub.edu

University of Barcelona



                 

https://researchid.co/jmarquez

RESEARCH, TEACHING, or OTHER INTERESTS

Psychology, Clinical Psychology, Psychiatry and Mental health, Neuropsychology and Physiological Psychology

18

Scopus Publications

343

Scholar Citations

11

Scholar h-index

12

Scholar i10-index

Scopus Publications

  • Could Periodontitis Increase the Risk of Suffering from Pancreatic Cancer?—A Systematic Review
    Cecilia Fabiana Márquez-Arrico, Francisco Javier Silvestre, Julia Elena Marquez-Arrico, and Javier Silvestre-Rangil

    MDPI AG
    (1) Background: The relationship between periodontitis and systemic pathologies continues to grow. Recently, the presence of periodontal pathogens has been linked to an increased risk of pancreatic cancer (PC) and its mortality. Thus, a systematic review is needed to identify whether an association between the two diseases can be established. The objective of this review is to elucidate the mechanisms responsible for this association. (2) Methods: A systematic review was carried out using three databases (PubMed, Embase and Scopus) with the following keywords “Periodontitis AND pancreatic cancer”. A total of 653 articles were retrieved; before selection and screening, the inclusion and exclusion criteria were defined, resulting in a total of 13 articles being included in the review. (3) Results: The increase in low-grade systemic inflammation, pH changes, and the cytotoxicity of certain periodontopathogenic bacteria were found in the scientific literature reviewed as mechanisms linking periodontitis with the risk of PC. (4) Conclusions: Through this systematic review, we have seen how periodontitis can be related to PC and how it worsens its prognosis. Knowing the behavior of periodontopathogenic bacteria and the influence they have on our immune and inflammatory system may help to achieve an interdisciplinary approach to both pathologies.

  • Circadian rhythmicity in schizophrenia male patients with and without substance use disorder comorbidity
    Ana Adan, Julia E. Marquez-Arrico, Laura Río-Martínez, José Francisco Navarro, and Antonio Martinez-Nicolas

    Springer Science and Business Media LLC
    AbstractCircadian rhythmicity is associated to clinical variables that play an important role in both schizophrenia (SZ) and substance use disorders (SUD), although the characteristics of the coexistence of these two diagnoses (SZ +) remain mostly unknown. Hence, we studied a sample of 165 male patients divided in three groups each of 55, according to their diagnoses (SZ + , SZ, and SUD), as well as a healthy control (HC; n = 90) group. Alongside with sociodemographic and clinical variables, circadian rhythms were registered through a sleep–wake data structured interview, a circadian typology questionnaire, and distal skin temperature (DST) using the Thermochron iButton every 2 min during 48 h. Analyses showed that SZ + and SZ patients presented a longer sleep (delay in wake-up time) and mostly an intermediate circadian typology, while SUD patients slept less hours, displaying a morning typology. The DST showed the highest daily activation and stability for the SUD group, even when compared with the HC group. The presence of schizophrenia (SZ + and SZ) was related to a DST pattern with a reduced amplitude determined by a wakefulness impairment, which was more pronounced for SZ patients whose sleep period was adequate. The assessment of circadian rhythms in under treatment male patients with SZ should be focused on the diurnal period as a possible marker of either treatment adherence or patient's recovery, irrespective of the presence of a comorbid SUD. Further research with additional objective measures may provide knowledge transferable to therapeutic strategies and could be useful to establish possible endophenotypes in the future.

  • Neuropsychological functioning of patients with major depression or bipolar disorder comorbid to substance use disorders: A systematic review
    Nuria Miguel, Julia E. Marquez-Arrico, Mercè Jodar, José Francisco Navarro, and Ana Adan

    Elsevier BV

  • Patients with Schizophrenia Showed Worse Cognitive Performance than Bipolar and Major Depressive Disorder in a Sample with Comorbid Substance Use Disorders
    Julia E. Marquez-Arrico, Alvaro Gonzalez-Sanchez, José Francisco Navarro, Rafael Penadés, and Ana Adan

    MDPI AG
    Comorbidity of substance use disorders (SUD) and severe mental illness (SMI) is highly frequent in patients, the most common diagnoses being schizophrenia (SZ), bipolar disorder (BD) and major depressive disorder (MDD). Since comorbidity has its own clinical features, and neurocognitive functioning is not always similar to psychiatric symptoms the present study explores the cognitive performance of patients with dual disorders. A neuropsychological battery of tests was used to assess 120 under treatment male patients, 40 for each group considered (SZ + SUD, BD + SUD and MDD + SUD) who were mainly polyconsumers. Significant differences (with premorbid IQ as a covariate) were found among the groups, with SZ + SUD having a worse performance in attention, verbal learning, short term memory and recognition. The consideration of a global Z score for performance evidenced an impaired neurocognitive pattern for SZ + SUD compared with BD + SUD and MDD + SUD. According to norms, all patients showed difficulties in verbal learning, short-term memory and recognition. Our research indicated that the neurocognitive functioning of dual disorder patients was influenced by the comorbid SMI, with SZ + SUD presenting major difficulties. Future studies should thoroughly explore the role of such difficulties as indicators or endophenotypes for dual schizophrenia disorders, and their usefulness for prevention and treatment.

  • Protocol for Characterization of Addiction and Dual Disorders: Effectiveness of Coadjuvant Chronotherapy in Patients with Partial Response
    Ana Adan, José Francisco Navarro, and

    MDPI AG
    This protocol aims to characterize patients with dual disorders (DD; comorbid major depression and schizophrenia) compared with patients with only a diagnosis of substance use disorder (SUD) and those with only a diagnosis of severe mental illness (SMI; major depression and schizophrenia), evaluating clinical and personality characteristics, circadian rhythmic functioning, genetic polymorphism and neuropsychological performance in order to obtain a clinical endophenotype of differential vulnerability for these diagnostic entities. Patients will be divided into three groups: DD (45 men with comorbid schizophrenia, 45 men and 30 women with major depression), SUD (n = 90, with a minimum of 30 women) and SMI males (45 with schizophrenia, 45 with major depression). All patients will be under treatment, with at least three months of SUD abstinence and/or with SMI in remission or with stabilized symptoms. Outpatients of both sexes with insufficient restoration of circadian rhythmicity with SUD (n = 30) and dual depression (n = 30) will be asked to participate in a second two-month study, being alternately assigned to the condition of the chronobiological adjuvant approach to the treatment of regular hour habits and exposure to light or to the usual treatment (control). The effect of the intervention and patient compliance will be monitored with a Kronowise KW6® ambulatory device during the first two weeks of treatment and again at weeks 4 and 8 weeks. After completing the evaluation, follow-up of the clinical evolution will be carried out at 3, 6 and 12 months. This project will allow us to analyze the functional impact of DD comorbidity and to develop the first study of chronobiological therapy in the treatment of SUD and dual depression, with results transferable to the clinical setting with cost-effective recommendations for a personalized approach.

  • Circadian Functioning and Quality of Life in Substance Use Disorder Patients With and Without Comorbid Major Depressive Disorder
    Iman Hashemzadeh, Julia E. Marquez-Arrico, Kosar Hashemzadeh, José Francisco Navarro, and Ana Adan

    Frontiers Media SA
    Aim: Although a relationship between circadian disruption and development of several psychiatric disorders, such as major depressive disorder (MDD) and substance use disorder (SUD), has been observed, knowledge on this area is scarce yet. Therefore, this study aims to analyze the circadian functioning and quality of life (QOL) in SUD patients with and without comorbid MDD, two highly prevalent clinical entities with difficult therapeutic management.Methods: One hundred sixty-three male patients under treatment, 81 with SUD and 82 with SUD comorbid major depressive disorder (SUD + MDD), were evaluated. For the circadian functioning assessment, we calculated Social Jet Lag (SJL) and used the reduced Morningness–Eveningness Questionnaire (rMEQ) and the Pittsburgh Sleep Quality Index (PSQI). QOL was measured using the shortened version of the World Health Organization's Quality of Life Questionnaire (WHOQOL-BREF). We collected sociodemographic and clinical variables to evaluate their possible influence on the circadian functioning. Intergroup differences among the variables were examined by different analyses of covariance (ANCOVA and MANCOVA). The possible relationships of quantitative clinical variables with rMEQ, PSQI, and WHOQOL-BREF were explored using bivariate correlation analysis.Results: Lower SJL appears in the SUD + MDD group compared with SUD. The intermediate-type was more prevalent in the SUD group, while a higher percentage of morning-type patients was found in the SUD + MDD. Sleep quality (including latency and daytime dysfunction) was worse for SUD + MDD patients than for SUD even after controlling age and age of SUD onset variables. Last, QOL was poorer in patients with SUD + MDD and, for them, psychological health had a negative relationship with SJL and severity of depression.Conclusions: Our data support and extend previous findings indicating that SUD + MDD is associated with worse clinical characteristics, more sleep problems, and poorer QOL than SUD patients. These results underline the importance of a precise assessment of these measurements in future studies conducted in SUD patients with/without MDD comorbidity that could be considered from a therapeutic point of view.

  • Circadian characteristics in patients under treatment for substance use disorders and severe mental illness (Schizophrenia, major depression and bipolar disorder)
    Ana Belén Serrano-Serrano, Julia E. Marquez-Arrico, José Francisco Navarro, Antonio Martinez-Nicolas, and Ana Adan

    MDPI AG
    Dual disorders (substance use and mental illness comorbidity) are a condition that has been strongly associated with severe symptomatology and clinical complications. The study of circadian characteristics in patients with Severe Mental Illness or Substance Use Disorder (SUD) has shown that such variables are related with mood symptoms and worse recovery. In absence of studies about circadian characteristics in patients with dual disorders we examined a sample of 114 male participants with SUD and comorbid Schizophrenia (SZ+; n = 38), Bipolar Disorder (BD+; n = 36) and Major Depressive Disorder (MDD+; n = 40). The possible differences in the sample of patients according to their psychiatric diagnosis, circadian functioning with recordings of distal skin temperature during 48 h (Thermochron iButton®), circadian typology and sleep-wake schedules were explored. MDD+ patients were more morning-type, while SZ+ and BD+ had an intermediate-type; the morning-type was more frequent among participants under inpatient SUD treatment. SZ+ patients had the highest amount of sleeping hours, lowest arousal and highest drowsiness followed by BD+ and MDD+, respectively. These observed differences suggest that treatment for patients with dual disorders could include chronobiological strategies to help them synchronize patterns with the day-light cycle, since morning-type is associated with better outcomes and recovery.

  • Premorbid functioning in schizophrenia spectrum disorders with comorbid substance use: A systematic review
    Gemma Prat, Julia E. Marquez-Arrico, Laura Río-Martínez, José Francisco Navarro, and Ana Adan

    Elsevier BV

  • Health-related quality of life in male patients under treatment for substance use disorders with and without major depressive disorder: Influence in clinical course at one-year follow-up
    Julia E. Marquez-Arrico, José Francisco Navarro, and Ana Adan

    MDPI AG
    Health-related quality of life (HRQoL) assessment has interest as an indicator of degree of affectation and prognosis in mental disorders. HRQoL is impaired in both Substance Use Disorder (SUD) and Major Depressive Disorder (MDD), two conditions highly prevalent, although less studied when both are coexisting (SUD + MDD). Hence, we decided to explore HRQoL with the SF-36 survey in a sample of 123 SUD and 114 SUD + MDD patients (51 symptomatic and 63 asymptomatic of depressive symptoms) under treatment. We performed analyses to examine HRQoL among groups, and its predictive value at 3-, 6- and 12-month follow-ups through regression models. Patients with SUD + MDD had worse HRQoL than SUD patients and population norms. For Mental Health, Vitality, and General Health dimensions, lower scores were observed for SUD + MDD regardless the presence/absence of depressive symptoms. For Physical Functioning and Health Change, depressive symptomatology and not the comorbidity of SUD + MDD diagnoses explained HRQoL limitations. At 3-, 6- and 12-month follow-ups we observed two predictors of relapses, General Health for asymptomatic SUD + MDD, and Physical Functioning for SUD. Improving HRQoL in SUD + MDD may be targeted during patient’s treatment; future studies should explore the influence of HRQoL on patient’s prognosis taking into account the presence/absence of depressive symptomatology.

  • Temperament and character profile and its clinical correlates in male patients with dual schizophrenia
    Laura Río-Martínez, Julia E. Marquez-Arrico, Gemma Prat, and Ana Adan

    MDPI AG
    Personality traits are relevant in understanding substance use disorders (SUD) and schizophrenia (SZ), but few works have also included patients with dual schizophrenia (SZ+) and personality traits. We explored personality profile in a sample of 165 male patients under treatment, using the Temperament and Character Inventory-Revised. The participants were assigned to three groups of 55 patients each, according to previous diagnosis: SUD, SZ- and SZ+ (without/with SUD). We analyzed their clinical characteristics, relating them to personality dimensions. The SUD and SZ+ groups scored higher than SZ- in Novelty/Sensation Seeking. SZ- and SZ+ presented higher Harm Avoidance and lower Persistence than the SUD group. SZ+ patients showed the lowest levels of Self-directedness, while SZ- and SZ+ had higher scores in Self-transcendence than the SUD group. Several clinical characteristics were associated with personality dimensions depending on diagnosis, and remarkably so for psychiatric symptoms in the SZ- and SZ+ groups. The three groups had a maladaptive personality profile compared to general population. Our results point to different profiles for SUD versus SZ, while both profiles appear combined in the SZ+ group, with extreme scores in some traits. Thus, considering personality endophenotypes in SZ+ could help in designing individualized interventions for this group.

  • Coping strategies in male patients under treatment for substance use disorders and/or severe mental illness: Influence in clinical course at one-year follow-up
    Julia Marquez-Arrico, Laura Río-Martínez, José Navarro, Gemma Prat, Diego Forero, and Ana Adan

    MDPI AG
    Coping strategies have an impact on substance use disorders (SUD), relapses, and clinical variables, but knowledge on this area is scarce. We explored the coping strategies used during treatment in patients with dual diagnosis (DD), SUD, and severe mental illness (SMI), and the relation with clinical course and relapses at one-year follow-up. A sample of 223 patients was divided into three groups depending on diagnosis: DD (N = 80; SUD with comorbid schizophrenia or major depressive disorder), SUD only (N = 80), and SMI only (N = 63; schizophrenia or major depressive disorder). MANCOVA analyses reflected differences in self-criticism and problem avoidance, with a higher use of these in the DD and SUD groups. The coping strategies used differed depending on the presence/absence of a SUD, but not depending on psychiatric diagnosis. At one-year follow-up, social support was the only strategy that predicted the presence of relapses in DD patients with schizophrenia (positively), and in SMI patients with major depressive disorder (negatively). Thus, social support was associated with relapses, but the relationship was different depending on psychiatric diagnosis. Further studies should analyze the implications of social support as a coping strategy in different mental disorders, as well as its usefulness in individualized interventions.

  • Personality profile and clinical correlates of patients with substance use disorder with and without comorbid depression under treatment
    Julia Elena Marquez-Arrico, Laura Río-Martínez, José Francisco Navarro, Gemma Prat, and Ana Adan

    Frontiers Media SA
    Background: Among patients with substance use disorder (SUD), major depressive disorder (MDD) is highly prevalent. Even though, personality plays an important role in treatment outcomes for individuals with SUD and SUD + MDD, few studies have explored personality characteristics in these samples. This study aims to describe personality for patients with SUD taking into account the comorbid MDD, using the Alternative Five Factor Model (AFFM). We also aim to compare SUD + MDD patients with population norms and to elucidate possible personality clinical correlates. Methods: For our study, 116 male patients undergoing for SUD treatment were divided in two groups: SUD only (N = 58) and SUD + MDD (N = 58). To examine personality, we used the Zuckerman-Kuhlman Personality Questionnaire and multiple analyses of covariance were performed to identify differences. In a first analysis, age was introduced as a covariate whereas in a second analysis the continuous variables that showed to have a discriminant value for the groups were added as covariates. Variables predicting the presence of dual diagnosis and personality clinical correlates were analyzed by logistic and linear regression models, respectively. We observed that patients with SUD + MDD show distinctive personality characteristics compared with patients with SUD only and population norms. Results: According to the AFFM, SUD + MDD patients are characterized by higher Neuroticism-Anxiety (positively associated to depressive symptoms) and Impulsivity; and by lower Parties and Friends. Moreover, the probability of having a dual depressive disorder was represented by the amount of medications and substances used. The preference for hard work and the energy self-reported levels (Work Activity trait) are linked to these clinical variables rather than to the presence/absence of a dual depressive disorder. Conclusions: Even when controlling clinical variables related to a higher probability of having a dual depressive disorder, the Neuroticism-Anxiety is a personality trait that strongly differentiates between SUD only and SUD + MDD patients. Further investigation is needed to explore the role of this personality trait as endophenotype in dual depressive men. Our results underline the importance of a dimensional understanding of personality and its clinical correlates among patients with SUD + MDD; this approach could provide us information on specific treatment strategies to improve the prognosis of patients.

  • Comparison of health-related quality of life among men with different co-existing severe mental disorders in treatment for substance use
    Ana Adan, Julia E. Marquez-Arrico, and Gail Gilchrist

    Springer Science and Business Media LLC

  • A Systematic Review and Meta-analysis of Psychosocial Interventions to Reduce Drug and Sexual Blood Borne Virus Risk Behaviours Among People Who Inject Drugs
    Gail Gilchrist, Davina Swan, Kideshini Widyaratna, Julia Elena Marquez-Arrico, Elizabeth Hughes, Noreen Dadirai Mdege, Marrissa Martyn-St James, and Judit Tirado-Munoz

    Springer Science and Business Media LLC




  • Dual diagnosis and personality traits: Current situation and future research directions
    Julia Elena Marquez-Arrico and Ana Adan

    Socidrogalcohol
    Dual diagnosis (DD) is the co-occurrence, in the same person, of a mental disorder (MD) and a substance use disorder (SUD). Nowadays, the study of the personality with DD is realized mainly from a categorical view, focusing on the detection of personality disorders and not on the traits associated to DD and the possible differential profile compared to those patients with only MD or SUD. Studies analyzing personality traits of patients with DD and their possible differential profile are very limited. However, existing data indicates that DD patients show higher levels of Sensation Seeking, Impulsivity, Harm Avoidance and Neuroticism; and lower levels of Persistence, Self-Direction, Self-Transcendence and Cooperation. Therefore, DD is associated to personality characteristics that suggest more disruptive behaviors, fewer resources for recovering and keeping abstinent and worse prognosis compared to those with only one disorder. Progress in the characterization of personality traits in DD, taking into consideration the methodological aspects to be improved could allow better adaptation of the integrated treatment of these patients in the future.

RECENT SCHOLAR PUBLICATIONS

  • Could Periodontitis Increase the Risk of Suffering from Pancreatic Cancer?—A Systematic Review
    CF Mrquez-Arrico, FJ Silvestre, JE Marquez-Arrico, J Silvestre-Rangil
    Cancers 16 (7), 1257 2024

  • Circadian rhythmicity in schizophrenia male patients with and without substance use disorder comorbidity
    A Adan, JE Marquez-Arrico, L Ro-Martnez, JF Navarro, ...
    European Archives of Psychiatry and Clinical Neuroscience 274 (2), 279-290 2024

  • Casos clnics psicofarmacologia. Grau de Psicologia Universitat de Barcelona.
    A Adan Puig, JE Marquez Arrico, JJ Soriano Raya, E Bedoya
    2023

  • Neuropsychological functioning of patients with major depression or bipolar disorder comorbid to substance use disorders: A systematic review
    N Miguel, JE Marquez-Arrico, M Jodar, JF Navarro, A Adan
    European Neuropsychopharmacology 75, 41-58 2023

  • Distal skin temperature in patients with substance use disorder: exploring sex-related differences in circadian parameters
    JE Marquez-Arrico, N Miguel, M Jodar, A Adan
    Neuroscience Applied 2, 102713 2023

  • Patients with schizophrenia showed worse cognitive performance than bipolar and major depressive disorder in a sample with comorbid substance use disorders
    JE Marquez-Arrico, A Gonzalez-Sanchez, JF Navarro, R Penads, ...
    Journal of Clinical Medicine 11 (22), 6648 2022

  • Circadian functioning and quality of life in substance use disorder patients with and without comorbid major depressive disorder
    I Hashemzadeh, JE Marquez-Arrico, K Hashemzadeh, JF Navarro, ...
    Frontiers in Psychiatry 12, 750500 2021

  • Circadian characteristics in patients under treatment for substance use disorders and severe mental illness (schizophrenia, major depression and bipolar disorder)
    AB Serrano-Serrano, JE Marquez-Arrico, JF Navarro, A Martinez-Nicolas, ...
    Journal of Clinical Medicine 10 (19), 4388 2021

  • Premorbid functioning in schizophrenia spectrum disorders with comorbid substance use: A systematic review
    G Prat, JE Marquez-Arrico, L Rio-Martinez, JF Navarro, A Adan
    Progress in Neuro-Psychopharmacology and Biological Psychiatry 110, 110310 2021

  • Health-related quality of life in male patients under treatment for substance use disorders with and without major depressive disorder: influence in clinical course at one-year
    JE Marquez-Arrico, JF Navarro, A Adan
    Journal of Clinical Medicine 9 (10), 3110 2020

  • Temperament and character profile and its clinical correlates in male patients with dual schizophrenia
    L Ro-Martnez, JE Marquez-Arrico, G Prat, A Adan
    Journal of clinical medicine 9 (6), 1876 2020

  • Coping strategies in male patients under treatment for substance use disorders and/or severe mental illness: Influence in clinical course at one-year follow-up
    JE Marquez-Arrico, L Ro-Martnez, JF Navarro, G Prat, DA Forero, ...
    Journal of Clinical Medicine 8 (11), 1972 2019

  • Personality profile and clinical correlates of patients with substance use disorder with and without comorbid depression under treatment
    JE Marquez-Arrico, L Ro-Martnez, JF Navarro, G Prat, A Adan
    Frontiers in psychiatry 9, 429948 2019

  • Personality traits of patients with dual disorders: A psychobiological approach
    JE Marquez-Arrico, L Rio-Martinez, G Prat, A Adan
    HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS 20, 61-61 2018

  • Circadian rhythms in Substance Use Disorders with and without depression
    A Adan, L Rio-Martinez, JE Marquez-Arrico, G Prat, JF Navarro
    HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS 20, 45-45 2018

  • Neuropsychological profile of dual despressed patients
    A Adan, JE Marquez-Arrico, L Rio-Martinez, G Prat
    HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS 20, 45-46 2018

  • Factors related to brain impairment in dual schizophrenia
    G Prat, L Rio-Martinez, JE Marquez-Arrico, D Forero, JF Navarro, A Adan
    HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS 20, 67-67 2018

  • Casos clnics. Assignatura de Psicofarmacologia
    A Adan Puig, G Prat, JE Marquez Arrico, JJ Soriano Raya
    2018

  • Comparison of health-related quality of life among men with different co-existing severe mental disorders in treatment for substance use
    A Adan, JE Marquez-Arrico, G Gilchrist
    Health and Quality of Life Outcomes 15, 1-12 2017

  • Personality in patients with dual diagnosis: The influence of severe mental illness
    JE Mrquez Arrico
    Universitat de Barcelona 2017

MOST CITED SCHOLAR PUBLICATIONS

  • Strategies to cope with treatment in substance use disorder male patients with and without schizophrenia
    JE Marquez-Arrico, I Benaiges, A Adan
    Psychiatry research 228 (3), 752-759 2015
    Citations: 62

  • Comparison of health-related quality of life among men with different co-existing severe mental disorders in treatment for substance use
    A Adan, JE Marquez-Arrico, G Gilchrist
    Health and Quality of Life Outcomes 15, 1-12 2017
    Citations: 36

  • A systematic review and meta-analysis of psychosocial interventions to reduce drug and sexual blood borne virus risk behaviours among people who inject drugs
    G Gilchrist, D Swan, K Widyaratna, JE Marquez-Arrico, E Hughes, ...
    AIDS and Behavior 21, 1791-1811 2017
    Citations: 35

  • Patologa dual y rasgos de personalidad: situacin actual y lneas futuras de trabajo
    JE Marquez Arrico, A Adan Puig
    Adicciones, 2013, vol. 25, num. 3, p. 195-202 2013
    Citations: 34

  • Temperament and character dimensions in male patients with substance use disorders: Differences relating to psychiatric comorbidity
    JE Marquez-Arrico, S Lpez-Vera, G Prat, A Adan
    Psychiatry research 237, 1-8 2016
    Citations: 26

  • Health-related quality of life in male patients under treatment for substance use disorders with and without major depressive disorder: influence in clinical course at one-year
    JE Marquez-Arrico, JF Navarro, A Adan
    Journal of Clinical Medicine 9 (10), 3110 2020
    Citations: 23

  • Coping strategies in male patients under treatment for substance use disorders and/or severe mental illness: Influence in clinical course at one-year follow-up
    JE Marquez-Arrico, L Ro-Martnez, JF Navarro, G Prat, DA Forero, ...
    Journal of Clinical Medicine 8 (11), 1972 2019
    Citations: 20

  • Temperament and character profile and its clinical correlates in male patients with dual schizophrenia
    L Ro-Martnez, JE Marquez-Arrico, G Prat, A Adan
    Journal of clinical medicine 9 (6), 1876 2020
    Citations: 19

  • Circadian characteristics in patients under treatment for substance use disorders and severe mental illness (schizophrenia, major depression and bipolar disorder)
    AB Serrano-Serrano, JE Marquez-Arrico, JF Navarro, A Martinez-Nicolas, ...
    Journal of Clinical Medicine 10 (19), 4388 2021
    Citations: 18

  • Personality in patients with substance use disorders according to the co-occurring severe mental illness: A study using the alternative five factor model
    JE Marquez-Arrico, A Adan
    Personality and Individual Differences 97, 76-81 2016
    Citations: 18

  • Personality profile and clinical correlates of patients with substance use disorder with and without comorbid depression under treatment
    JE Marquez-Arrico, L Ro-Martnez, JF Navarro, G Prat, A Adan
    Frontiers in psychiatry 9, 429948 2019
    Citations: 17

  • Neuropsychological functioning of patients with major depression or bipolar disorder comorbid to substance use disorders: A systematic review
    N Miguel, JE Marquez-Arrico, M Jodar, JF Navarro, A Adan
    European Neuropsychopharmacology 75, 41-58 2023
    Citations: 10

  • Circadian functioning and quality of life in substance use disorder patients with and without comorbid major depressive disorder
    I Hashemzadeh, JE Marquez-Arrico, K Hashemzadeh, JF Navarro, ...
    Frontiers in Psychiatry 12, 750500 2021
    Citations: 9

  • Premorbid functioning in schizophrenia spectrum disorders with comorbid substance use: A systematic review
    G Prat, JE Marquez-Arrico, L Rio-Martinez, JF Navarro, A Adan
    Progress in Neuro-Psychopharmacology and Biological Psychiatry 110, 110310 2021
    Citations: 7

  • Patients with schizophrenia showed worse cognitive performance than bipolar and major depressive disorder in a sample with comorbid substance use disorders
    JE Marquez-Arrico, A Gonzalez-Sanchez, JF Navarro, R Penads, ...
    Journal of Clinical Medicine 11 (22), 6648 2022
    Citations: 6

  • Circadian rhythmicity in schizophrenia male patients with and without substance use disorder comorbidity
    A Adan, JE Marquez-Arrico, L Ro-Martnez, JF Navarro, ...
    European Archives of Psychiatry and Clinical Neuroscience 274 (2), 279-290 2024
    Citations: 3